The impact of the #EMBARK trial on treatment decisions in high-risk biochemical recurrent #ProstateCancer . Neal Shore CURC joins Zach Klaassen Georgia Cancer Center to discuss findings and potential future research directions > bit.ly/3U9esH2

Amer. Urol. Assn. surgical guidelines for #BPH : From patient assessment to procedure selection. A #JournalClub discussion with Rashid K. Sayyid University of Toronto & Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/3u4b1bM

Navigating the Nuances: Exploring imaging options and impact to treatment strategies in #nmCPRC . Ryan Malone, MD First Urology joins Zach Klaassen Georgia Cancer Center in this conversation focusing on the evolving role of PSMA PET imaging. #WatchNow > bit.ly/42lRAaT Bayer U.S. 🇺🇸

The impact of the #EMBARK trial on treatment decisions in high-risk biochemical recurrent #ProstateCancer . Neal Shore CURC joins Zach Klaassen Georgia Cancer Center to discuss findings and potential future research directions > bit.ly/3U9esH2

Operationalizing #BlueLight in your practice - Gautam Jayram, MD Urology Associates and Zach Klaassen explore the use of blue light cystoscopy and the potential future applications in image-guided therapies > bit.ly/3RJ1sYH Wellstar Health System Photocure

#ASCO24 is quickly approaching! If you haven't already, don't forget to sign up for email coverage delivered straight to your inbox! #FollowUs on #SoMe to stay up to date for upcoming events and live coverage throughout the conference > bit.ly/3QbtkmW ASCO #ASCO2024

Best practices for successfully implementing triplet therapy in #mHSPC . Chris Pieczonka AMP and Zach Klaassen Georgia Cancer Center discuss managing mHSPC emphasizing the shift from ADT monotherapy to triple therapy. #WatchNow > bit.ly/3UndFUb

Systematic review sheds light on treatment intensification in metastatic #ProstateCancer . Peter J. Goebell FAU Erlangen-Nbg and Zach Klaassen Georgia Cancer Center discuss if scientific evidence, as outlined in guidelines, translates into real-world practice changes > bit.ly/4ch0MSu

Exploring the landscape of #mHSPC treatment in #NorthAmerica . Check out this insightful review on the implementation of treatment strategies and the importance of disease volume and timing of metastasis in guiding optimal therapy > bit.ly/3sBomr7 Zach Klaassen Rashid K. Sayyid

The quickly evolving treatment landscape of metastatic #UrothelialCarcinoma : a new standard of care in first-line systemic therapy. Zach Klaassen Georgia Cancer Center and Rashid K. Sayyid University of Toronto review developments in the treatment of metastatic urothelial carcinoma > bit.ly/3PlZjR2

Non-metastatic CRPC in the era of PSMA PET imaging: Challenges and opportunities. Aaron Berger, MD Associated Urological Specialists joins Zach Klaassen Georgia Cancer Center to discuss the evolving landscape of #nmCRPC . #WatchNow > bit.ly/3Q5qWhy

Genetic testing reveals treatment opportunity and disparity in advanced #ProstateCancer . Colin Pritchard University of Washington joins Zach Klaassen Georgia Cancer Center emphasizing the importance of genomic testing for treatment decisions and family counseling. #WatchNow > bit.ly/3GRRbmO

Cretostimogene Grenadenorepvec therapy aims to fill an unmet need in the #BladderCancer armamentarium. Robert Svatek, MD UT Health San Antonio joins Zach Klaassen Georgia Cancer Center to discuss in this conversation on UroToday. #WatchNow > bit.ly/4anMbnp CG Oncology, Inc.

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

KEYNOTE-564 1-yr adjuvant pembro OS data hitting in NEJM today

Congrats Toni Choueiri, MD et al

Huge for the field and our high-risk localized RCC patients!

UroToday.com Georgia Cancer Center

nejm.org/doi/full/10.10…

Amer. Urol. Assn. guidelines provide a roadmap for assessing disease burden and personalizing systemic therapies in #mHSPC . Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center discuss on UroToday > bit.ly/3vupApb

Novel targets and treatment developments in metastatic hormone-sensitive #ProstateCancer . Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center discuss on UroToday > bit.ly/47AvQJR

PARP inhibitor monotherapy for #ProstateCancer patients. Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center provide an in-depth overview of the current evidence summarizing efficacy results from major trials and the adverse event profile of these agents > bit.ly/3TKfY3l

Epidemiological trends and treatment innovations in advanced #ProstateCancer : An in-depth analysis of the Amer. Urol. Assn. amended 2023 guidelines. #JournalClub Rashid K. Sayyid University of Toronto & Zach Klaassen Georgia Cancer Center discuss on UroToday > bit.ly/3RW6X5b